The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy
Open accessAbstract
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as undesirable "side effects." In contrast, we believe ketamine can benefit patients with a wide variety of diagnoses when administered with psychotherapy and using its psychedelic properties without need for intravenous (IV) access. Its proven safety over decades of use makes it ideal for office and supervised at-home use. The unique experience that ketamine facilitates with its biological, experiential, and psychological impacts has been tailored to optimize office-based treatment evolving into a method that we call Ketamine Assisted Psychotherapy (KAP). This article is the first to explore KAP within an analytical framework examining three distinct practices that use similar methods. Here, we present demographic and outcome data from 235 patients. Our findings suggest that KAP is an effective method for decreasing depression and anxiety in a private practice setting, especially for older patients and those with severe symptom burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since all psychedelics exert effects rapidly and are known to induce mystical-type, peak, or transcendental effects that are correlated with therapeutic outcomes (Dore et al., 2019;Johnson et al., 2019;Barrett and Griffiths, 2018), these treatments may be especially helpful in the context of existential distress (Rosenbaum et al., 2019).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Dore et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Concerns have been raised regarding feasibility, repeated administration, and the lack of clarity surrounding long-term outcomes when rapid-acting agents are used without concurrent psychotherapeutic support [78].”
From Targeting Psychological Pain After a Suicide Attempt: Scoping Review and Intervention Protocol (2026) · cites this paper as [78]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“In the late 1990s, investigators at the National Institute of Mental Health began exploring the antidepressant potential of ketamine while searching for alternatives to the limited benefits of SSRIs and SNRIs (Berman et al. 2000; Krystal et al. 1994).”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · cited 1×
“In our offices, we make every effort to provide a nest in the Winnicott sense, a place of safety and warmth (Carhart-Harris et al. 2018).”
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Psychedelics, meditation, and self-consciousness
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01475 · Cited by 390 · cited 1×
“The journey tends to augment meditative ability and stability (Millière et al. 2018).”
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 1×
“However, studies from the IV researchers indicated enhanced benefit from the presence of psychedelic experiences (Luckenbaugh et al. 2014).”
Internal family systems therapy
(1998) · PsycEXTRA Dataset · doi:10.1037/e537692004-001 · Cited by 247
Research works printed but not linked: 12
- Brown D. A., 2016, Attachment disorder in adults
- Early T., 2016, The ketamine papers: Science,therapy and transformation, 305
- Fontana A., 1974, Acta psiquiatrica y psicologica de America latina, 20, 32
- Jaitly V., 2013, Journal of Observational Pain Medicine, 1
- Krystal J. H., 2007, Swiss Medical Weekly, 137, 215
- 10.3389/fnhum.2016.00269.eCollection2016 · doi:10.3389/fnhum.2016.00269.ecollection2016
- 10.1016/j.biopsych.2009.08.038 · DOI · Paper page
- Ryan W., 2016, The ketamine papers, 199
- Weber F., 2004, Paediatr†anaesth, 14, 983
- Wieber J., 1975, Anaesthesist, 24, 260
- Wolfson P., 2016, The ketamine papers
- Yensen R., 2016, The ketamine papers, 69
Cited by
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
Metadata
- Authors
- Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P.
- Affiliations
- Helios Psychiatry, Woodside, CA
- Roots Behavioral Health, Austin, TX
- Center for Transformational Psychotherapy, San Anselmo, CA
- Ketamine Research Foundation, San Anselmo, CA
- Corresponding author
- Wolfson, Phil
- Venue
- Journal of Psychoactive Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-03-15
- Volume
- 51
- Issue
- 2
- Pages
- 189-198
- ISSN
- 0279-1072 (ISSN-L)
- 2159-9777
- OpenAlex
- W2932518772
- Cited by
- 217
- References
- 36
- Citations by year
- 2026: 39 · 2025: 30 · 2024: 33 · 2023: 34 · 2022: 42 · 2021: 28 · 2020: 9 · 2019: 2
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Psychoactive Drugs (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- None of the authors of this paper have a financial interest or benefit arising from the direct applications of this research
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine-assisted psychotherapy, ketamine, psychedelic medicine, treatment-resistant depression, depression, anxiety, patient demographics, treatment outcomes, elderly patients, symptom burden
- MeSH terms
- Adult, Anxiety, Combined Modality Therapy, Depression, Female, Hallucinogens, Humans, Ketamine, Male, Psychotherapy, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. https://app.cochat.ai/papers/10.1080/02791072.2019.1587556
- The paper
- Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2019.1587556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.